Publicaciones en colaboración con investigadores/as de Hospital General Universitario de Valencia (21)

2022

  1. Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

    European Journal of Surgical Oncology, Vol. 48, Núm. 5, pp. 1123-1132

2021

  1. First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

    Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231

  2. Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications

    JCO oncology practice, Vol. 17, Núm. 8, pp. e1162-e1169

2020

  1. Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion

    Clinical Colorectal Cancer, Vol. 19, Núm. 3, pp. 165-177

  2. Treatment patterns for metastatic colorectal cancer in Spain

    Clinical and Translational Oncology, Vol. 22, Núm. 9, pp. 1455-1462

2019

  1. Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: Retrospective analyses of two phase II randomised Spanish TTD trials

    ESMO Open, Vol. 4, Núm. 6

  2. Working towards a consensus on the oncological approach of breakthrough pain: A Delphi survey of Spanish experts

    Journal of Pain Research, Vol. 12, pp. 2349-2358

2018

  1. A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer

    Clinical Colorectal Cancer, Vol. 17, Núm. 2, pp. e323-e329

2017

  1. European edition of the NCCN clinical practice guidelines: relevance of the translation and adaptation into Spanish

    Clinical and Translational Oncology, Vol. 19, Núm. 3, pp. 288-290

  2. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)

    European Journal of Cancer, Vol. 81, pp. 191-202

2016

  1. Quality indicators to assure and improve cancer care in Spain using the delphi technique

    JNCCN Journal of the National Comprehensive Cancer Network, Vol. 14, Núm. 5, pp. 553-558

2014

  1. Oncological translational research in the Spanish national health system: The INTRO study

    Clinical and Translational Oncology, Vol. 16, Núm. 8, pp. 686-695

  2. Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists

    Clinical and Translational Oncology, Vol. 16, Núm. 10, pp. 914-920

2012

  1. Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

    PLoS ONE, Vol. 7, Núm. 10

2011

  1. Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04)

    Clinical and Translational Oncology, Vol. 13, Núm. 6, pp. 411-418

2009

  1. Retrospective study of efficacy and toxicity on patients older than 70 years within a randomized clinical trial of two cisplatin-based combinations in patients with small-cell lung cancer

    Lung Cancer, Vol. 63, Núm. 1, pp. 83-87

2005

  1. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: A Spanish Cooperative Group for the Treatment of Digestive Tumors study

    Journal of Clinical Oncology, Vol. 23, Núm. 15, pp. 3545-3551

  2. Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer

    Annals of Oncology, Vol. 16, Núm. 4, pp. 597-601

2004

  1. Prospective randomised phase III trial of etoposide/cisplatin versus high-dose epirubicin/cisplatin in small-cell lung cancer

    Clinical Lung Cancer, Vol. 6, Núm. 3, pp. 175-183

2003

  1. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: A study by the GEICAM group

    Annals of Oncology, Vol. 14, Núm. 6, pp. 833-842